Zynerba Pharmaceuticals

$11.90
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.03 (-0.25%) Today
$0.00 (0.00%) As of 4:15 PM EDT after-hours

Why Robinhood?

You can buy or sell ZYNE and other stocks, options, ETFs, and crypto commission-free!

About ZYNE

Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. It engages in the development and commercialization of transdermal pharmaceutically-produced cannabinoid treatments for rare and near-rare neurological and psychiatric, or neuropsychiatric, disorders in patients with high unmet medical needs. Read More The company was founded by Audra L. Stinchcomb on January 31, 2007 and is headquartered in Devon, PA.

Employees
25
Headquarters
Devon, Pennsylvania
Founded
2007
Market Cap
276.06M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
838.57K
High Today
$12.51
Low Today
$11.56
Open Price
$11.99
Volume
992.34K
52 Week High
$16.47
52 Week Low
$2.75

Collections

ZYNE Earnings

-$0.91
-$0.75
-$0.60
-$0.44
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Estimated
Actual
Expected Nov 7, Pre-Market

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.